CTLA4 and cancer: Following the FDA approval of Ipilimumab (a CTLA-4 inhibitor) for advanced melanoma in 2011, ICIs quickly gained approval for treating various cancer types (19), as evidenced by several FDA-approved immune checkpoints such as PD-1 and its receptor PD-L1, CTLA-4, and LAG3.